Unibest

Pharmaceutical intermediates

Cenobamate Intermediates

3 pharmaceutical intermediates for Cenobamate. Indication: Partial seizures; epileptic seizures; epilepsy.

提交项目All intermediates

About Cenobamate

Originator
SK Biopharmaceuticals Co Ltd
Indication
Partial seizures; epileptic seizures; epilepsy
Approved Date
03/10/2020
NCE Patent
03/10/2025
DS/DP
10/30/2032

Available intermediates

3 intermediates currently listed for Cenobamate. Request specifications, documentation or a quotation for any item below.

Cenobamate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Bromo-2'-chloroacetophenone5000-66-8//
1-(2-chlorophenyl)-2-(1,2,3,4-tetrazol-2-yl)ethan-1-one1259059-71-6//
Cenobamate N-1 intermediate1259059-77-2//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Cenobamate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →